Our extensive database of Harvard technologies is available for new product development opportunities that will strengthen your strategic portfolio.

The Harvard University Office of Technology Development (OTD) provides a one-stop shop to advance the development of groundbreaking discoveries by fostering strategic collaborations with industry through licensing, sponsored research and new venture agreements.

Impact

Turning today's discoveries into tomorrow's transformational technologies.

By serving as a catalyst bridging the laboratory to industry, OTD ensures that promising new technologies are developed into products and services that benefit society and transform the world.

Leadership

Leading the way in discovery and application.

Harvard is a recognized world leader in discovery and innovation. Leadership means the determination to see that new technologies developed at Harvard reach their full potential and push the boundaries of the new scientific and industrial frontier.

Experience

At OTD, experience is a competitive advantage.

OTD's high performance team provides a solid foundation in science, business development, intellectual property and contract law that enables it to design creative "win-win" solutions that translate into enduring, fruitful relationships. When industry turns to OTD, it will find an agile, fast-paced group of professionals fully equipped to find creative solutions and make the deal-making process as efficient and effective as possible.

Partnership

The power of collaborative partnering.

Partnership is a vital pillar, a linchpin of OTD's business model. We have the focus, commitment and expertise to forge creative and productive partnerships. OTD is dedicated to fostering win/win relationships between faculty and industry, investors and entrepreneurs, relationships that will provide mutual and long-lasting benefit.

Blavatnik Biomedical Accelerator

Propelling promising Harvard life science innovations to partnership

To positively impact society, biomedical technology breakthroughs must first make the leap from the research lab to the commercial sphere. The Blavatnik Biomedical Accelerator at Harvard University is uniquely structured to bridge that gap, helping propel groundbreaking innovations toward next-generation products.

Available Technology

Novel means of protecting the cell against oncogenic tumor formation



Technology:
Identification of a sequence element from p53 that signals for Mdm2-targeted Deg

Markets Addressed


Both peptide delivery and gene therapy represent promising venues for developing this technology . In one embodiment, delivery of these peptides by either anti-Mdm2 or anti-E6 antibody tagged liposome-mediated transfer will selectively kill the cancer cells and have no effect on normal cells.

Innovations and Advantages


Research at Harvard University has led to a novel means of protecting the cell against oncogenic tumor formation. This invention provides compositions and methods for inhibiting degradation of tumor suppressor protein p53, thereby enhancing p53-mediated growth-suppressive properties. This technology shows particular promise in gene therapy applications.

The p53 protein is a transcription factor involved in the control of cell cycle progression, DNA integrity, and the survival of cells exposed to DNA damaging agents. Activation of p53 generally results in cycle arrest, a critical step towards the repair of cells with genomic mutations that may result in cellular transformation. Loss of p53 activity, therefore, predisposes cells to the acquisition of oncogenic mutations.

Oncoproteins Mdm2 and E6 both inactivate p53 tumor suppressor activity by promoting p53 degradation. Unusually high levels of Mdm2 are found in many tumor types with wild type p53, and the human papillomavirus E6 protein is etiologically involved in the development of cervical cancer.

A seven (7) amino acid sequence element from p53 that functions as a degradation signal for both the Mdm2 and human papillomavirus E6 oncoproteins has been pinpointed. A small peptide derived from the degradation signal sequence of p53 can efficiently block Mdm2- and E6-mediated degradation of p53. Inhibition of p53 degradation will result in an increase of p53 protein levels and therefore restore its tumor suppressor function.

Additional Information




Inventor(s):
    Chen, Dongli
    Gu, Jijie
    Rosenblum, Jamie
    Rubin, Rachel
    Yuan, Zhi-Min

Categories:
For further information, please contact:
Debra Peattie, Director of Business Development
(617) 495-3067
Reference Harvard Case #1659